CTMX-2009-002, NCT04596150: Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer |
|
|
| Completed | 2 | 125 | Europe, US, RoW | CX-2009, CX-072 | CytomX Therapeutics | Neoplasms, Breast Neoplasms, Breast Neoplasms, Triple-Negative, Breast Cancer, Breast Neoplasms, Hormone Receptor Positive/HER2 Negative | 06/23 | 06/23 | | |
2020-004618-36: Study to test CX-2009 in Advanced HR-Positive/HER2-Negative Breast Cancer and of CX-2009 as Monotherapy and in Combination with CX-072 in Advanced Triple-Negative Breast Cancer Estudio para evaluar CX-2009 en el cáncer de mama avanzado positivo para receptores hormonales/negativo para el receptor HER2, y de CX-2009 como monoterapia y en combinación con CX-072 en el cáncer de mama avanzado triple negativo (CTMX-2009-002) |
|
|
| Not yet recruiting | 2 | 150 | Europe | CX-2009, CX-072, CX-2009, CX-072, Powder for infusion, Solution for infusion | CytomX Therapeutics, Inc., CytomX Therapeutics, Inc. | HR-positive/HER2-negative breast cancerTriple-negative breast cancer Cáncer de mama positivo para receptores hormonales/negativo para elreceptor HER2Cáncer de mama avanzado triple negativo, Breast Cancer Cáncer de mama, Diseases [C] - Cancer [C04] | | | | |
